175 related articles for article (PubMed ID: 20352234)
1. Multidisciplinary treatment of giant invasive prolactinomas in paediatric age: long-term follow-up in two children.
Fraioli MF; Novegno F; Catena E; Fraioli C; Moschettoni L
Childs Nerv Syst; 2010 Sep; 26(9):1233-7. PubMed ID: 20352234
[TBL] [Abstract][Full Text] [Related]
2. Giant prolactinomas: the therapeutic approach.
Moraes AB; Silva CM; Vieira Neto L; Gadelha MR
Clin Endocrinol (Oxf); 2013 Oct; 79(4):447-56. PubMed ID: 23662975
[TBL] [Abstract][Full Text] [Related]
3. Giant, solid, invasive prolactinoma in a prepubescent boy with gynecomastia.
Furtado SV; Saikiran NA; Ghosal N; Hegde AS
Pediatr Neurol; 2010 Jan; 42(1):72-4. PubMed ID: 20004869
[TBL] [Abstract][Full Text] [Related]
4. Giant Prolactinomas.
Shimon I
Neuroendocrinology; 2019; 109(1):51-56. PubMed ID: 30404098
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome of multimodal therapy for giant prolactinomas.
Andujar-Plata P; Villar-Taibo R; Ballesteros-Pomar MD; Vidal-Casariego A; Pérez-Corral B; Cabezas-Agrícola JM; Álvarez-Vázquez P; Serramito R; Bernabeu I
Endocrine; 2017 Jan; 55(1):231-238. PubMed ID: 27704480
[TBL] [Abstract][Full Text] [Related]
6. Giant prolactinomas in adolescence: an uncommon cause of blindness.
Semple P; Fieggen G; Parkes J; Levitt N
Childs Nerv Syst; 2007 Feb; 23(2):213-7. PubMed ID: 16983572
[TBL] [Abstract][Full Text] [Related]
7. Giant prolactinomas: clinical management and long-term follow up.
Shrivastava RK; Arginteanu MS; King WA; Post KD
J Neurosurg; 2002 Aug; 97(2):299-306. PubMed ID: 12186457
[TBL] [Abstract][Full Text] [Related]
8. Combined treatment of invasive giant prolactinomas.
Yu C; Wu Z; Gong J
Pituitary; 2005; 8(1):61-5. PubMed ID: 16411070
[TBL] [Abstract][Full Text] [Related]
9. Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas.
Shimon I; Sosa E; Mendoza V; Greenman Y; Tirosh A; Espinosa E; Popovic V; Glezer A; Bronstein MD; Mercado M
Pituitary; 2016 Aug; 19(4):429-36. PubMed ID: 27138902
[TBL] [Abstract][Full Text] [Related]
10. Giant prolactinomas in men: efficacy of cabergoline treatment.
Corsello SM; Ubertini G; Altomare M; Lovicu RM; Migneco MG; Rota CA; Colosimo C
Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
[TBL] [Abstract][Full Text] [Related]
11. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
[TBL] [Abstract][Full Text] [Related]
12. Therapy of endocrine disease: the challenges in managing giant prolactinomas.
Maiter D; Delgrange E
Eur J Endocrinol; 2014 Jun; 170(6):R213-27. PubMed ID: 24536090
[TBL] [Abstract][Full Text] [Related]
13. Giant prolactinomas presenting as skull base tumors.
Minniti G; Jaffrain-Rea ML; Santoro A; Esposito V; Ferrante L; Delfini R; Cantore G
Surg Neurol; 2002 Feb; 57(2):99-103; discussion 103-4. PubMed ID: 11904200
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis, treatment, and outcome of pituitary tumors and other abnormal intrasellar masses. Retrospective analysis of 353 patients.
Gsponer J; De Tribolet N; Déruaz JP; Janzer R; Uské A; Mirimanoff RO; Reymond MJ; Rey F; Temler E; Gaillard RC; Gomez F
Medicine (Baltimore); 1999 Jul; 78(4):236-69. PubMed ID: 10424206
[TBL] [Abstract][Full Text] [Related]
15. Giant invasive prolactinomas.
Murphy FY; Vesely DL; Jordan RM; Flanigan S; Kohler PO
Am J Med; 1987 Nov; 83(5):995-1002. PubMed ID: 3674103
[TBL] [Abstract][Full Text] [Related]
16. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.
Andereggen L; Frey J; Andres RH; El-Koussy M; Beck J; Seiler RW; Christ E
Endocrine; 2017 Jan; 55(1):223-230. PubMed ID: 27688009
[TBL] [Abstract][Full Text] [Related]
17. Treatments of multi-invasive giant prolactinoma.
Yang MY; Shen CC; Ho WL
J Clin Neurosci; 2004 Jan; 11(1):70-5. PubMed ID: 14642373
[TBL] [Abstract][Full Text] [Related]
18. Surgery as a Viable Alternative First-Line Treatment for Prolactinoma Patients. A Systematic Review and Meta-Analysis.
Zamanipoor Najafabadi AH; Zandbergen IM; de Vries F; Broersen LHA; van den Akker-van Marle ME; Pereira AM; Peul WC; Dekkers OM; van Furth WR; Biermasz NR
J Clin Endocrinol Metab; 2020 Mar; 105(3):e32-41. PubMed ID: 31665485
[TBL] [Abstract][Full Text] [Related]
19. Long-term management of prolactinomas.
Schlechte JA
J Clin Endocrinol Metab; 2007 Aug; 92(8):2861-5. PubMed ID: 17682084
[TBL] [Abstract][Full Text] [Related]
20. Prolactinomas in men masquerading as invasive skull base tumours.
Cook RJ; Uttley D; Wilkins PR; Archer DJ; Bell BA
Br J Neurosurg; 1994; 8(1):51-5. PubMed ID: 8011194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
